NASDAQ$NUVL
Nuvalent Inc · Q2 2024 earnings
Q2 2024 earnings · · Before market open · Investor relations
Briefing
Nuvalent Inc reported a net loss of $57.2 million for Q2 2024 as it advanced its clinical-stage oncology programs.
The company continued to incur significant operating expenses driven by research and development activities for its lead product candidates zidesamtinib, NVL-655, and NVL-330. Cash and cash equivalents stood at $77.7 million with marketable securities providing additional liquidity. No revenue was generated during the quarter.
- R&D expenses increased to $49.2 million, reflecting expanded clinical trial activities and manufacturing costs.
- G&A expenses rose to $16.0 million, primarily due to higher stock-based compensation and personnel costs.
- Net loss widened to $57.2 million compared to $29.1 million in the prior-year quarter.
- Company maintains strong liquidity position with $658.0 million in cash, cash equivalents, and marketable securities.
Headline financials
Revenue & EPS history
Nuvalent · Revenue · Quarterly
$0
Forward guidance
Company plans to provide clinical updates on zidesamtinib and NVL-655 at ESMO Congress in September 2024 while advancing NVL-330 in Phase 1.
Tailwinds
- Multiple product candidates advancing in clinical development with regulatory designations.
- Sufficient cash runway into 2027 to support ongoing programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports
-0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-7.7%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+14.6%
Q4 2021
Best reaction
-5.0%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q4 2025 | -0.5% | -4.1% | -7.5% | |
| Q3 2025 | -5.0% | -11.6% | +6.2% | |
| Q1 2025 | +3.2% | +3.7% | +10.2% | |
| Q4 2024 | -2.8% | -7.0% | -5.2% | |
| Q3 2024 | -4.3% | -8.0% | -8.0% | |
| Q1 2024 | -3.1% | +0.7% | +17.2% | |
| Q4 2023 | -1.4% | +0.6% | -13.3% | |
| Q3 2023 | +3.7% | +5.0% | +38.8% | |
| Q2 2023 | -1.1% | -3.1% | +9.2% | |
| Q1 2023 | -2.5% | -1.1% | +3.5% | |
| Q4 2022 | +8.3% | +4.7% | +0.9% | |
| Q3 2022 | +1.0% | +2.9% | -2.1% | |
| Q2 2022 | +4.5% | +9.3% | +13.1% | |
| Q1 2022 | -0.7% | +7.3% | +16.1% | |
| Q4 2021 | +14.6% | +20.2% | -8.1% | |
| Q3 2020 | +1.3% | -14.7% | -2.4% | |
| Q3 2021 | +1.3% | -10.4% | -20.1% | |
| Q2 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2021 | -4.3% | -2.9% | -52.6% | |
| Q2 2021 | -4.3% | -2.9% | -52.6% | |
| Q4 2020 | -4.3% | -2.9% | -52.6% | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro